# Clinical Trials Data KIT - Document 57

# Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease

## Clinical Trial: https://clinicaltrials.gov/study/NCT00743418

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with MCI, Alzheimer's disease, or mixed type dementia; OR\n\* Healthy control subjects who meet the following criteria:\n\n \* Mini Mental State (MMSE) of at least 21\n \* Age 60 years or older\n \* Patients with history of stroke which is not followed by cognitive decline may be included\n \* Fluent language skills\n\nExclusion Criteria:\n\n\* Other dementias (e.g. vascular, frontotemporal, metabolic etc);\n\* Other major psychiatric disorders (e.g. major depression, schizophrenia);\n\* Substance abuse;\n\* MMSE 20 or less;\n\* Severe motor disturbances;\n\* Sensory deficits potentially affecting mobility; OR\n\* Severe physical disorders (e.g. cancer, major operation)",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "60 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention KIT gene mutations\*\* as either an inclusion or exclusion criterion. Therefore, we cannot determine from this information alone whether a patient with a KIT mutation would be eligible.   
  
A KIT mutation could potentially impact eligibility if it leads to a condition that falls under one of the listed exclusion criteria (e.g., a severe physical disorder like cancer). Conversely, if the patient with the KIT mutation has MCI, Alzheimer's, mixed dementia, or meets the healthy control criteria, they \*might\* be eligible.  
  
More information is needed about the specific implications of the patient's KIT mutation to assess their eligibility. It's crucial for the patient to discuss their specific situation with the clinical trial investigators.